Biocon

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by 2 agencies.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 10% and profit rose 54% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 45%, down from 54% in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 72.5 times its yearly earnings (P/E), pricier than 77% of the time in the last 5 years. Its usual P/E is about 28.

Biocon against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)72.5 against a typical 33.2: pricier than most peers (1st = cheapest).177th of 220
• Sales growth+10% against a typical +15.6% from a year earlier.115th of 197
• Profit growth+53.9% against a typical +18.9% from a year earlier.50th of 160
• Share price, 3 months−18.6% against a typical −1.8%.177th of 200
• Size₹ 53,225.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).13th of 199

Exchange filings and their impact on the company.

• 26 Oct 2026UpdatesLow impactPositivePrice +1.6% that day
  Biocon cleared to sell its Stelara biosimilar Yesintek in 9 more countries, expanding its global opportunity.

  Biocon has signed a licence agreement with Janssen allowing commercialization of Yesintek, its proposed biosimilar to Stelara (ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect. This builds on earlier agreements securing entry in the US, Europe, UK, Canada and Japan. The reference brand Stelara had worldwide sales of $6.08 billion in 2025, and launches in the new markets remain subject to regulatory approval.

  Full analysisFiling
• 14 Oct 2026UpdatesMedium impactPositivePrice −0.1% that day
  Biocon settled globally with Genentech to secure earliest licensed launch for its Perjeta biosimilar starting in EU in early 2027.

  Biocon has signed a global settlement and license agreement with Genentech resolving all patent disputes over pertuzumab in the US, Canada and other countries. The deal gives Biocon the earliest licensed launch dates for Pebrilzo, its biosimilar to Perjeta for HER2-positive breast cancer, in the EU and UK in Q1 2027, in the US in Q3 2028, and in other world markets during 2026-2028. This clears a key legal hurdle and positions Biocon as an early entrant, with EU sales able to contribute within the next 12 months subject to regulatory approval.

  Full analysisFiling
• 10 Oct 2026General UpdatesLow impactNegativePrice −0.9% on 12 Oct
  Biocon received a state tax Order-In-Original with no disclosed amount, expected to be immaterial.

  Biocon on October 10, 2026 disclosed receipt of an Order-In-Original from the Assistant Commissioner (State Tax), Atchuthapuram circle, Visakhapatnam-2 in Andhra Pradesh. The filing refers to Form A details under SEBI Regulation 30 but no demand amount, penalty or period was visible in the extracted text. The order relates to state tax and does not indicate any operational restriction, so the near-term financial impact is expected to be small and subject to appeal or payment.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Kiran Mazumdar-Shaw

Executive Chairperson of the Board

Shreehas Pradeep Tambe

Chief Executive Officer, Managing Director, Additional Director

Kedar Narayan Upadhye

Chief Financial Officer

Rajesh Umakant Shanoy

Compliance Officer, Company Secretary

Akhilesh Nand

Head - Governance, Risk and Compliance